Payment overview · 2025
General Payments
$252.62
13 reported records · 7 companies
Healthcare provider profile · identity verified
Andrea Avalos, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAMPTON, VA · NPI 1710483680
Verified facts
What the public records show
CMS Open Payments records show Andrea Avalos, MD received $252.62 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.31 | 25.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.12 | 25.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.39 | 16.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.08 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.98 | 7.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.00 | 7.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.74 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.62 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.12 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 124 |
| Gabapentin | Gabapentin | 223 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 56 |
| Metformin Hcl | Metformin Hcl | 160 | 48 |
| Lisinopril | Lisinopril | 156 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 51 |
| Omeprazole | Omeprazole | 151 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 31 |
| Furosemide | Furosemide | 118 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 42 |
| Losartan Potassium | Losartan Potassium | 113 | 35 |
| Carvedilol | Carvedilol | 111 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 38 |
| Montelukast Sodium | Montelukast Sodium | 108 | 33 |
| Glipizide | Glipizide | 97 | 34 |
| Simvastatin | Simvastatin | 88 | 30 |
| Meloxicam | Meloxicam | 85 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 17 |
| Ozempic | Semaglutide | 83 | 17 |
| Alendronate Sodium | Alendronate Sodium | 80 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 26 |
| Spironolactone | Spironolactone | 73 | 19 |
| Glipizide Er | Glipizide | 72 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 22 |
| Allopurinol | Allopurinol | 69 | 17 |
| Lovastatin | Lovastatin | 69 | 23 |
| Metformin Hcl Er | Metformin Hcl | 69 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 24 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 25 |
| Pregabalin | Pregabalin | 57 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 21 |
| Atenolol | Atenolol | 52 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | 13 |
| Linzess | Linaclotide | 49 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 15 |
| Trazodone Hcl | Trazodone Hcl | 49 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 16 |
| Celecoxib | Celecoxib | 48 | 14 |
| Ibuprofen | Ibuprofen | 47 | 22 |
| Famotidine | Famotidine | 43 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Eliquis | Apixaban | 42 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | 11 |
| Prednisone | Prednisone | 39 | 36 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Methocarbamol | Methocarbamol | 37 | 16 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 13 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Baclofen | Baclofen | 33 | 13 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 28 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Naproxen | Naproxen | 23 | 14 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.62 · 13 records | Novo Nordisk Inc | CAPVAXIVE, GARDASIL 9, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, REPATHA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error